Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiopharmaceuticals | 12 | 2025 | 2703 | 2.100 |
Why?
|
Hodgkin Disease | 11 | 2025 | 1384 | 2.080 |
Why?
|
Radionuclide Imaging | 7 | 2023 | 1986 | 1.760 |
Why?
|
Neuroblastoma | 14 | 2023 | 1266 | 1.550 |
Why?
|
Fluorodeoxyglucose F18 | 8 | 2025 | 2028 | 1.290 |
Why?
|
Osteoma, Osteoid | 2 | 2023 | 94 | 1.220 |
Why?
|
Paraganglioma | 3 | 2022 | 143 | 1.000 |
Why?
|
Bone Neoplasms | 8 | 2023 | 2561 | 0.950 |
Why?
|
Positron-Emission Tomography | 14 | 2024 | 6548 | 0.930 |
Why?
|
Oropharynx | 2 | 2020 | 139 | 0.820 |
Why?
|
Pheochromocytoma | 2 | 2022 | 327 | 0.790 |
Why?
|
Radioisotope Renography | 1 | 2022 | 61 | 0.780 |
Why?
|
Gastric Emptying | 2 | 2022 | 247 | 0.780 |
Why?
|
3-Iodobenzylguanidine | 3 | 2023 | 114 | 0.770 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2022 | 732 | 0.760 |
Why?
|
Population Surveillance | 3 | 2019 | 2594 | 0.720 |
Why?
|
Diagnostic Techniques, Digestive System | 1 | 2020 | 45 | 0.710 |
Why?
|
Neoplasm Staging | 15 | 2025 | 11218 | 0.710 |
Why?
|
Hepatoblastoma | 3 | 2018 | 90 | 0.700 |
Why?
|
Child | 67 | 2025 | 80670 | 0.700 |
Why?
|
Embolic Protection Devices | 1 | 2019 | 43 | 0.640 |
Why?
|
Tomography, X-Ray Computed | 12 | 2025 | 20710 | 0.620 |
Why?
|
Neck Injuries | 1 | 2020 | 162 | 0.620 |
Why?
|
Spinal Neoplasms | 2 | 2023 | 714 | 0.600 |
Why?
|
Intracranial Embolism | 1 | 2019 | 188 | 0.580 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2017 | 134 | 0.550 |
Why?
|
Receptors, Interleukin-2 | 10 | 2010 | 565 | 0.550 |
Why?
|
Sternotomy | 1 | 2018 | 134 | 0.550 |
Why?
|
Neoplasms | 21 | 2024 | 22350 | 0.540 |
Why?
|
Postural Balance | 1 | 2021 | 637 | 0.540 |
Why?
|
Surgical Wound Dehiscence | 1 | 2018 | 215 | 0.540 |
Why?
|
Magnetic Resonance Imaging | 19 | 2025 | 36570 | 0.510 |
Why?
|
Foreign Bodies | 1 | 2020 | 403 | 0.510 |
Why?
|
Wilms Tumor | 1 | 2018 | 378 | 0.500 |
Why?
|
Interleukin-2 | 13 | 2010 | 1895 | 0.490 |
Why?
|
Bone Plates | 1 | 2018 | 468 | 0.470 |
Why?
|
Gait | 1 | 2020 | 823 | 0.470 |
Why?
|
Adolescent | 50 | 2025 | 88902 | 0.460 |
Why?
|
Lymph Nodes | 1 | 2025 | 3468 | 0.420 |
Why?
|
Growth Plate | 1 | 2014 | 275 | 0.410 |
Why?
|
Chest Tubes | 1 | 2013 | 153 | 0.410 |
Why?
|
Diagnostic Imaging | 10 | 2024 | 3530 | 0.410 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2019 | 1374 | 0.400 |
Why?
|
Radiometry | 1 | 2017 | 814 | 0.390 |
Why?
|
Child, Preschool | 34 | 2024 | 42577 | 0.380 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2014 | 415 | 0.370 |
Why?
|
Kidney Diseases | 1 | 2022 | 2101 | 0.360 |
Why?
|
Heart Valve Prosthesis | 1 | 2019 | 1464 | 0.350 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 2023 | 0.350 |
Why?
|
Aortic Valve | 2 | 2022 | 1966 | 0.340 |
Why?
|
Granuloma, Plasma Cell | 2 | 2022 | 80 | 0.340 |
Why?
|
Liver Neoplasms | 5 | 2020 | 4356 | 0.340 |
Why?
|
Humans | 122 | 2025 | 766812 | 0.330 |
Why?
|
Medical Oncology | 3 | 2022 | 2340 | 0.330 |
Why?
|
Reference Values | 3 | 2021 | 4914 | 0.320 |
Why?
|
Whole Body Imaging | 2 | 2024 | 283 | 0.320 |
Why?
|
Body Burden | 1 | 2009 | 156 | 0.320 |
Why?
|
Sarcoma, Synovial | 1 | 2010 | 157 | 0.320 |
Why?
|
Databases, Factual | 3 | 2021 | 8065 | 0.310 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2024 | 5330 | 0.300 |
Why?
|
Fatty Liver | 3 | 2013 | 810 | 0.300 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 11876 | 0.300 |
Why?
|
Immunoconjugates | 3 | 2015 | 976 | 0.290 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2024 | 9407 | 0.290 |
Why?
|
Drainage | 1 | 2013 | 1182 | 0.290 |
Why?
|
Tibia | 1 | 2013 | 1071 | 0.280 |
Why?
|
Radiation Protection | 2 | 2017 | 425 | 0.280 |
Why?
|
Bronchial Neoplasms | 1 | 2007 | 109 | 0.280 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2007 | 91 | 0.280 |
Why?
|
Pediatrics | 3 | 2011 | 3614 | 0.270 |
Why?
|
Copper Radioisotopes | 3 | 2015 | 99 | 0.270 |
Why?
|
Thoracic Surgery | 1 | 2013 | 727 | 0.270 |
Why?
|
Contrast Media | 5 | 2019 | 5329 | 0.270 |
Why?
|
Wound Healing | 1 | 2018 | 2800 | 0.270 |
Why?
|
Radiography, Thoracic | 1 | 2013 | 1320 | 0.270 |
Why?
|
Bronchopulmonary Sequestration | 1 | 2006 | 43 | 0.270 |
Why?
|
Imaging, Three-Dimensional | 2 | 2018 | 4047 | 0.260 |
Why?
|
Fluorescent Dyes | 1 | 2014 | 1927 | 0.250 |
Why?
|
Young Adult | 20 | 2025 | 59939 | 0.250 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 2057 | 0.240 |
Why?
|
Female | 60 | 2025 | 396532 | 0.240 |
Why?
|
Male | 52 | 2025 | 364154 | 0.240 |
Why?
|
Tomography, Emission-Computed | 1 | 2007 | 1006 | 0.240 |
Why?
|
Killer Cells, Natural | 6 | 1998 | 2209 | 0.230 |
Why?
|
Cyclopentanes | 1 | 2024 | 87 | 0.230 |
Why?
|
Retrospective Studies | 19 | 2024 | 81657 | 0.230 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2631 | 0.230 |
Why?
|
Central Nervous System Neoplasms | 3 | 2024 | 926 | 0.220 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 168 | 0.220 |
Why?
|
Maximum Tolerated Dose | 7 | 2024 | 896 | 0.220 |
Why?
|
Neurofibromatoses | 2 | 2017 | 303 | 0.210 |
Why?
|
Pyrimidines | 3 | 2024 | 3043 | 0.210 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1433 | 0.210 |
Why?
|
Aniline Compounds | 2 | 2010 | 1079 | 0.210 |
Why?
|
Minors | 1 | 2023 | 59 | 0.210 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13489 | 0.210 |
Why?
|
Lipodystrophy | 1 | 2024 | 145 | 0.210 |
Why?
|
Technetium Tc 99m Mertiatide | 1 | 2022 | 22 | 0.200 |
Why?
|
Diagnosis, Differential | 7 | 2024 | 12985 | 0.200 |
Why?
|
Gadolinium | 2 | 2017 | 964 | 0.200 |
Why?
|
Neurilemmoma | 2 | 2017 | 522 | 0.190 |
Why?
|
Kidney Neoplasms | 2 | 2018 | 4282 | 0.190 |
Why?
|
Surface Plasmon Resonance | 1 | 2022 | 268 | 0.190 |
Why?
|
Glomus Tumor | 1 | 2022 | 62 | 0.190 |
Why?
|
Dairy Products | 1 | 2005 | 490 | 0.190 |
Why?
|
Antibodies, Monoclonal | 12 | 2024 | 9244 | 0.190 |
Why?
|
Infant | 21 | 2023 | 36459 | 0.190 |
Why?
|
Indenes | 1 | 2021 | 59 | 0.180 |
Why?
|
Severe Combined Immunodeficiency | 5 | 1998 | 235 | 0.180 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2024 | 283 | 0.180 |
Why?
|
Plasmacytoma | 1 | 2001 | 171 | 0.180 |
Why?
|
Cheese | 1 | 2020 | 39 | 0.180 |
Why?
|
Polycythemia | 1 | 2021 | 124 | 0.180 |
Why?
|
Lymphoma | 4 | 2023 | 1899 | 0.180 |
Why?
|
Phantoms, Imaging | 3 | 2023 | 2474 | 0.180 |
Why?
|
Pyridines | 3 | 2018 | 2888 | 0.170 |
Why?
|
Organometallic Compounds | 1 | 2024 | 647 | 0.170 |
Why?
|
Polyneuropathies | 1 | 2001 | 139 | 0.170 |
Why?
|
Diffusion Magnetic Resonance Imaging | 4 | 2013 | 2809 | 0.170 |
Why?
|
Lymphocyte Activation | 11 | 1998 | 5502 | 0.170 |
Why?
|
Luminescent Proteins | 1 | 2002 | 839 | 0.170 |
Why?
|
Yoga | 1 | 2023 | 277 | 0.160 |
Why?
|
Eggs | 1 | 2020 | 182 | 0.160 |
Why?
|
Alkaline Phosphatase | 1 | 2002 | 855 | 0.160 |
Why?
|
Lipids | 2 | 2013 | 3322 | 0.160 |
Why?
|
Protein Kinase Inhibitors | 5 | 2022 | 5690 | 0.160 |
Why?
|
Water | 1 | 2005 | 1416 | 0.160 |
Why?
|
Leukemia | 3 | 2019 | 1521 | 0.160 |
Why?
|
Salvage Therapy | 2 | 2018 | 1274 | 0.160 |
Why?
|
Biliary Tract Diseases | 1 | 1999 | 159 | 0.160 |
Why?
|
Receptors, Mitogen | 1 | 1998 | 61 | 0.150 |
Why?
|
Radiation Dosage | 3 | 2023 | 1958 | 0.150 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2022 | 616 | 0.150 |
Why?
|
Fibroblast Growth Factors | 1 | 2024 | 871 | 0.150 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2023 | 1143 | 0.150 |
Why?
|
Lectins, C-Type | 2 | 1998 | 592 | 0.140 |
Why?
|
Breast | 1 | 2006 | 1972 | 0.140 |
Why?
|
Optic Nerve Glioma | 1 | 2017 | 32 | 0.140 |
Why?
|
Pancreatic Diseases | 1 | 1999 | 353 | 0.140 |
Why?
|
Sarcoma | 2 | 2022 | 1802 | 0.140 |
Why?
|
Pyrazoles | 3 | 2019 | 2030 | 0.140 |
Why?
|
Fanconi Syndrome | 1 | 2017 | 35 | 0.140 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2017 | 68 | 0.140 |
Why?
|
Radiation, Ionizing | 1 | 2017 | 251 | 0.140 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.140 |
Why?
|
Radiation Injuries | 1 | 2024 | 1195 | 0.140 |
Why?
|
Neoplasm, Residual | 2 | 2020 | 1012 | 0.130 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2017 | 117 | 0.130 |
Why?
|
Ischemic Attack, Transient | 1 | 2022 | 874 | 0.130 |
Why?
|
Amyloid | 1 | 2001 | 849 | 0.130 |
Why?
|
Lipectomy | 1 | 2017 | 114 | 0.130 |
Why?
|
Foot | 1 | 2020 | 576 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2022 | 1621 | 0.130 |
Why?
|
von Hippel-Lindau Disease | 1 | 2017 | 154 | 0.130 |
Why?
|
Parotid Neoplasms | 1 | 2017 | 158 | 0.130 |
Why?
|
Food | 1 | 2020 | 764 | 0.130 |
Why?
|
Prognosis | 8 | 2018 | 29959 | 0.130 |
Why?
|
Melanoma | 4 | 2010 | 5702 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1144 | 0.120 |
Why?
|
Antineoplastic Agents | 6 | 2019 | 13644 | 0.120 |
Why?
|
Genetic Vectors | 2 | 2002 | 3401 | 0.120 |
Why?
|
Titanium | 1 | 2018 | 494 | 0.120 |
Why?
|
Anilides | 1 | 2018 | 413 | 0.120 |
Why?
|
Consensus | 1 | 2025 | 3208 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5753 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 2 | 2002 | 3738 | 0.120 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2022 | 2426 | 0.110 |
Why?
|
Affinity Labels | 1 | 2014 | 107 | 0.110 |
Why?
|
Tetrahydrofolate Dehydrogenase | 1 | 2014 | 133 | 0.110 |
Why?
|
Antigens, CD | 5 | 1998 | 4033 | 0.110 |
Why?
|
Follow-Up Studies | 8 | 2017 | 39312 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 5 | 2017 | 8928 | 0.110 |
Why?
|
Rhodamines | 1 | 2014 | 179 | 0.110 |
Why?
|
Iodine Radioisotopes | 1 | 2017 | 1030 | 0.110 |
Why?
|
Molecular Probes | 1 | 2015 | 309 | 0.110 |
Why?
|
Chelating Agents | 2 | 2015 | 384 | 0.110 |
Why?
|
Tacrolimus Binding Proteins | 1 | 2014 | 199 | 0.110 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2002 | 1836 | 0.100 |
Why?
|
Soybean Oil | 1 | 2013 | 139 | 0.100 |
Why?
|
Lymphoproliferative Disorders | 1 | 2016 | 527 | 0.100 |
Why?
|
Hemangioma | 1 | 2017 | 727 | 0.100 |
Why?
|
Neurofibromatosis 1 | 1 | 2017 | 561 | 0.100 |
Why?
|
Time Factors | 7 | 2022 | 40149 | 0.100 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2017 | 724 | 0.100 |
Why?
|
Prenatal Diagnosis | 2 | 2009 | 1271 | 0.100 |
Why?
|
Cohort Studies | 5 | 2018 | 41706 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 385 | 0.090 |
Why?
|
Liver Diseases | 1 | 1999 | 1303 | 0.090 |
Why?
|
Lymphedema | 1 | 2017 | 526 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 1600 | 0.090 |
Why?
|
Treatment Outcome | 13 | 2022 | 65286 | 0.090 |
Why?
|
Diet, Fat-Restricted | 1 | 2013 | 328 | 0.090 |
Why?
|
Homeostasis | 1 | 2022 | 3343 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4903 | 0.090 |
Why?
|
Transcription Factors | 2 | 2017 | 12159 | 0.090 |
Why?
|
Adult | 17 | 2024 | 223305 | 0.090 |
Why?
|
Fat Emulsions, Intravenous | 1 | 2013 | 314 | 0.090 |
Why?
|
Membrane Glycoproteins | 2 | 1998 | 3702 | 0.090 |
Why?
|
Cholestasis | 1 | 2013 | 385 | 0.090 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3235 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2002 | 5143 | 0.080 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2016 | 617 | 0.080 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2011 | 161 | 0.080 |
Why?
|
Fish Oils | 1 | 2013 | 483 | 0.080 |
Why?
|
Intestinal Atresia | 1 | 2009 | 69 | 0.080 |
Why?
|
Pylorus | 1 | 2009 | 86 | 0.080 |
Why?
|
Disease-Free Survival | 5 | 2023 | 6853 | 0.080 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 1990 | 897 | 0.080 |
Why?
|
Tumor Cells, Cultured | 6 | 2002 | 6105 | 0.080 |
Why?
|
Thyroid Nodule | 1 | 2016 | 765 | 0.080 |
Why?
|
Thymus Neoplasms | 3 | 2005 | 272 | 0.080 |
Why?
|
Small Molecule Libraries | 1 | 2014 | 741 | 0.080 |
Why?
|
Neoplasm Transplantation | 2 | 2015 | 2012 | 0.080 |
Why?
|
Hemodynamics | 1 | 2019 | 4188 | 0.080 |
Why?
|
Keratins | 1 | 2010 | 499 | 0.080 |
Why?
|
Kidney | 2 | 2022 | 7073 | 0.080 |
Why?
|
Meningioma | 1 | 2017 | 1221 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2019 | 3440 | 0.080 |
Why?
|
Relative Biological Effectiveness | 1 | 2009 | 313 | 0.070 |
Why?
|
Asparaginase | 1 | 2009 | 240 | 0.070 |
Why?
|
Liver | 3 | 2020 | 7571 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2017 | 5860 | 0.070 |
Why?
|
Diseases in Twins | 1 | 2009 | 447 | 0.070 |
Why?
|
Infant, Newborn | 8 | 2017 | 26387 | 0.070 |
Why?
|
Cross-Linking Reagents | 1 | 2010 | 689 | 0.070 |
Why?
|
Pain Measurement | 1 | 2018 | 3576 | 0.070 |
Why?
|
Observer Variation | 1 | 2013 | 2614 | 0.070 |
Why?
|
Recurrence | 3 | 2019 | 8507 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2012 | 6514 | 0.070 |
Why?
|
Artifacts | 2 | 2013 | 1897 | 0.070 |
Why?
|
Pubic Symphysis Diastasis | 1 | 2006 | 2 | 0.070 |
Why?
|
Musculoskeletal Diseases | 1 | 2013 | 598 | 0.070 |
Why?
|
Pubic Symphysis | 1 | 2006 | 21 | 0.070 |
Why?
|
Pattern Recognition, Automated | 1 | 2013 | 980 | 0.070 |
Why?
|
Leukemia, Erythroblastic, Acute | 2 | 1998 | 176 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 18076 | 0.070 |
Why?
|
Anesthesia | 1 | 2017 | 1595 | 0.070 |
Why?
|
Patient Care Team | 1 | 2017 | 2519 | 0.070 |
Why?
|
Transplantation, Autologous | 2 | 2023 | 2127 | 0.070 |
Why?
|
Abdomen | 1 | 2012 | 1137 | 0.070 |
Why?
|
Algorithms | 5 | 2013 | 14073 | 0.060 |
Why?
|
Cell Line, Tumor | 5 | 2022 | 17089 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2016 | 2233 | 0.060 |
Why?
|
Diffusion | 3 | 2012 | 808 | 0.060 |
Why?
|
Ovariectomy | 2 | 2019 | 612 | 0.060 |
Why?
|
Phlebography | 1 | 2006 | 326 | 0.060 |
Why?
|
beta Catenin | 1 | 2010 | 1048 | 0.060 |
Why?
|
Cloning, Molecular | 3 | 2002 | 4168 | 0.060 |
Why?
|
Brain Neoplasms | 3 | 2017 | 9101 | 0.060 |
Why?
|
X Chromosome | 4 | 1995 | 819 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2017 | 2329 | 0.060 |
Why?
|
Osteolysis | 1 | 2006 | 273 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2017 | 9613 | 0.060 |
Why?
|
Hospitals | 1 | 2017 | 3885 | 0.060 |
Why?
|
Models, Molecular | 1 | 2014 | 5388 | 0.050 |
Why?
|
Thymoma | 1 | 2005 | 186 | 0.050 |
Why?
|
Sulfonamides | 1 | 2013 | 1982 | 0.050 |
Why?
|
Molecular Structure | 1 | 2007 | 1882 | 0.050 |
Why?
|
Mice | 11 | 2024 | 81898 | 0.050 |
Why?
|
Diagnostic Errors | 1 | 2010 | 1276 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 3 | 2006 | 3186 | 0.050 |
Why?
|
Fetal Diseases | 1 | 2008 | 915 | 0.050 |
Why?
|
Nonlinear Dynamics | 1 | 2005 | 490 | 0.050 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 2 | 1993 | 283 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2018 | 3683 | 0.050 |
Why?
|
Switzerland | 1 | 2023 | 322 | 0.050 |
Why?
|
Pancreatitis | 1 | 2009 | 1087 | 0.050 |
Why?
|
Normetanephrine | 1 | 2021 | 25 | 0.050 |
Why?
|
Image Enhancement | 1 | 2013 | 2858 | 0.050 |
Why?
|
Veins | 1 | 2006 | 769 | 0.050 |
Why?
|
DNA, Recombinant | 1 | 2002 | 455 | 0.050 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2024 | 249 | 0.050 |
Why?
|
Escherichia coli | 1 | 2014 | 4211 | 0.050 |
Why?
|
Risk Assessment | 3 | 2019 | 24299 | 0.050 |
Why?
|
Quinazolines | 1 | 2008 | 1367 | 0.050 |
Why?
|
Killer Cells, Lymphokine-Activated | 3 | 1992 | 42 | 0.050 |
Why?
|
Organs at Risk | 1 | 2024 | 367 | 0.050 |
Why?
|
Aneurysm, False | 1 | 2004 | 264 | 0.050 |
Why?
|
Risk Factors | 6 | 2022 | 74889 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2023 | 8715 | 0.050 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily D | 2 | 1998 | 30 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2712 | 0.050 |
Why?
|
Protein Binding | 1 | 2014 | 9326 | 0.050 |
Why?
|
Remission Induction | 2 | 2018 | 2413 | 0.050 |
Why?
|
Combined Modality Therapy | 4 | 2019 | 8540 | 0.050 |
Why?
|
Aged | 6 | 2023 | 171344 | 0.050 |
Why?
|
Peptide Library | 1 | 2002 | 351 | 0.050 |
Why?
|
Cell Nucleus | 1 | 2010 | 2875 | 0.050 |
Why?
|
Animals | 15 | 2024 | 168939 | 0.050 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.050 |
Why?
|
Sclerosis | 1 | 2001 | 211 | 0.050 |
Why?
|
Lymphocytes | 1 | 1989 | 2606 | 0.040 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2013 | 1399 | 0.040 |
Why?
|
Adenoids | 1 | 2020 | 35 | 0.040 |
Why?
|
Cause of Death | 1 | 2011 | 3717 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5536 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2022 | 59548 | 0.040 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 1561 | 0.040 |
Why?
|
Palate, Soft | 1 | 2020 | 100 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2013 | 3360 | 0.040 |
Why?
|
Protons | 1 | 2005 | 1101 | 0.040 |
Why?
|
Molecular Sequence Data | 5 | 2002 | 17609 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2010 | 892 | 0.040 |
Why?
|
Palatine Tonsil | 1 | 2020 | 193 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2011 | 11062 | 0.040 |
Why?
|
Amino Acid Sequence | 4 | 2002 | 13411 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9744 | 0.040 |
Why?
|
Cell Communication | 2 | 1998 | 1660 | 0.040 |
Why?
|
Melanoma, Experimental | 1 | 2002 | 557 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2013 | 3989 | 0.040 |
Why?
|
Crohn Disease | 1 | 2012 | 2286 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2022 | 518 | 0.040 |
Why?
|
Hypoplastic Left Heart Syndrome | 1 | 2004 | 595 | 0.040 |
Why?
|
Bacteriophages | 1 | 2002 | 382 | 0.040 |
Why?
|
Adrenal Glands | 1 | 2021 | 556 | 0.040 |
Why?
|
Postoperative Complications | 2 | 2016 | 15831 | 0.040 |
Why?
|
Pelvis | 1 | 2023 | 737 | 0.040 |
Why?
|
Expert Testimony | 1 | 2020 | 266 | 0.040 |
Why?
|
Blood Glucose | 1 | 2013 | 6422 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2020 | 877 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2019 | 418 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2023 | 811 | 0.040 |
Why?
|
DNA Primers | 1 | 2002 | 2826 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 10745 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 3 | 1996 | 1352 | 0.040 |
Why?
|
Radiography | 3 | 2005 | 6968 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 1998 | 313 | 0.040 |
Why?
|
Radiotherapy | 1 | 2024 | 1497 | 0.040 |
Why?
|
Retreatment | 1 | 2019 | 598 | 0.040 |
Why?
|
Blood Sedimentation | 1 | 2018 | 234 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2019 | 385 | 0.030 |
Why?
|
Tongue | 1 | 2020 | 406 | 0.030 |
Why?
|
Green Fluorescent Proteins | 1 | 2002 | 2062 | 0.030 |
Why?
|
Dacarbazine | 2 | 2010 | 552 | 0.030 |
Why?
|
Radiology | 1 | 2010 | 2105 | 0.030 |
Why?
|
Parotid Gland | 1 | 2017 | 178 | 0.030 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 1999 | 520 | 0.030 |
Why?
|
Glioma | 1 | 2011 | 3498 | 0.030 |
Why?
|
Exercise Therapy | 1 | 2023 | 935 | 0.030 |
Why?
|
Neurofibromin 2 | 1 | 2017 | 269 | 0.030 |
Why?
|
Medical Informatics Applications | 1 | 2017 | 180 | 0.030 |
Why?
|
Preoperative Care | 2 | 2019 | 2253 | 0.030 |
Why?
|
Neurofibromin 1 | 1 | 2017 | 190 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 26309 | 0.030 |
Why?
|
Fetus | 1 | 2023 | 1878 | 0.030 |
Why?
|
Peripheral Vascular Diseases | 1 | 1998 | 488 | 0.030 |
Why?
|
Pulmonary Artery | 1 | 2004 | 1938 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15425 | 0.030 |
Why?
|
Eating | 1 | 2022 | 1539 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2275 | 0.030 |
Why?
|
Syndrome | 1 | 2021 | 3271 | 0.030 |
Why?
|
Graft Occlusion, Vascular | 1 | 1998 | 538 | 0.030 |
Why?
|
Immunoglobulins | 1 | 1998 | 853 | 0.030 |
Why?
|
Multigene Family | 1 | 1998 | 1081 | 0.030 |
Why?
|
Aza Compounds | 1 | 2015 | 34 | 0.030 |
Why?
|
Middle Aged | 6 | 2023 | 223267 | 0.030 |
Why?
|
Erythroid Precursor Cells | 1 | 1995 | 211 | 0.030 |
Why?
|
Precipitin Tests | 2 | 1998 | 816 | 0.030 |
Why?
|
Embolization, Therapeutic | 1 | 2004 | 1403 | 0.030 |
Why?
|
Survival Rate | 3 | 2016 | 12826 | 0.030 |
Why?
|
Arm | 1 | 2017 | 591 | 0.030 |
Why?
|
Static Electricity | 1 | 2015 | 258 | 0.030 |
Why?
|
Executive Function | 1 | 2023 | 1396 | 0.030 |
Why?
|
Drug Evaluation | 3 | 1992 | 642 | 0.030 |
Why?
|
Radiology, Interventional | 1 | 1998 | 483 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2823 | 0.030 |
Why?
|
Reproducibility of Results | 4 | 2013 | 20146 | 0.030 |
Why?
|
Base Sequence | 2 | 2002 | 12415 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2002 | 6066 | 0.030 |
Why?
|
Microbial Viability | 1 | 2014 | 236 | 0.030 |
Why?
|
Dipeptides | 1 | 2015 | 386 | 0.030 |
Why?
|
Models, Structural | 1 | 1993 | 339 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3511 | 0.030 |
Why?
|
Dimerization | 1 | 2014 | 882 | 0.030 |
Why?
|
Leg | 1 | 2017 | 1087 | 0.030 |
Why?
|
COS Cells | 1 | 2014 | 1135 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2011 | 3610 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2004 | 3831 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 1998 | 1417 | 0.020 |
Why?
|
Structure-Activity Relationship | 2 | 1995 | 3053 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2011 | 3552 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2005 | 3429 | 0.020 |
Why?
|
Cytokines | 2 | 1998 | 7438 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2012 | 368 | 0.020 |
Why?
|
Indazoles | 1 | 2013 | 306 | 0.020 |
Why?
|
Mycobacterium | 1 | 1993 | 252 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 1998 | 1802 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2024 | 9546 | 0.020 |
Why?
|
Protein Engineering | 1 | 2015 | 554 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12536 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2016 | 1131 | 0.020 |
Why?
|
Human Body | 1 | 2011 | 36 | 0.020 |
Why?
|
Flow Cytometry | 2 | 1992 | 5890 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 1993 | 354 | 0.020 |
Why?
|
Ultrasonography, Prenatal | 2 | 2009 | 1772 | 0.020 |
Why?
|
Spectrometry, Fluorescence | 1 | 1993 | 694 | 0.020 |
Why?
|
Obesity | 1 | 2013 | 13090 | 0.020 |
Why?
|
Glycemic Index | 1 | 2013 | 400 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 1729 | 0.020 |
Why?
|
Burkitt Lymphoma | 1 | 1993 | 338 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3605 | 0.020 |
Why?
|
Macromolecular Substances | 1 | 1993 | 1431 | 0.020 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2010 | 68 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2013 | 608 | 0.020 |
Why?
|
Organ Specificity | 1 | 2015 | 1968 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2002 | 2186 | 0.020 |
Why?
|
Gestational Age | 2 | 2009 | 3617 | 0.020 |
Why?
|
Vinblastine | 1 | 2011 | 482 | 0.020 |
Why?
|
Polyhydramnios | 1 | 2009 | 41 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4523 | 0.020 |
Why?
|
Diet, Reducing | 1 | 2013 | 487 | 0.020 |
Why?
|
CHO Cells | 1 | 1992 | 1376 | 0.020 |
Why?
|
Biotin | 1 | 1990 | 255 | 0.020 |
Why?
|
Heterocyclic Compounds | 1 | 2010 | 245 | 0.020 |
Why?
|
Pregnancy | 3 | 2023 | 30236 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 1998 | 1285 | 0.020 |
Why?
|
Binding, Competitive | 1 | 1990 | 1141 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2012 | 993 | 0.020 |
Why?
|
Motion | 1 | 2013 | 783 | 0.020 |
Why?
|
Heat-Shock Proteins | 1 | 1993 | 792 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 1998 | 6225 | 0.020 |
Why?
|
Fetal Movement | 1 | 2008 | 21 | 0.020 |
Why?
|
Cricetinae | 1 | 1992 | 2416 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3618 | 0.020 |
Why?
|
Parenteral Nutrition | 1 | 2013 | 661 | 0.020 |
Why?
|
Computer Simulation | 2 | 2012 | 6258 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2010 | 794 | 0.020 |
Why?
|
Dietary Carbohydrates | 1 | 2013 | 896 | 0.020 |
Why?
|
Carboplatin | 1 | 2011 | 790 | 0.020 |
Why?
|
HeLa Cells | 1 | 2014 | 3073 | 0.020 |
Why?
|
Intra-Abdominal Fat | 1 | 2013 | 624 | 0.020 |
Why?
|
Histocompatibility Antigens | 1 | 1989 | 479 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 1997 | 6507 | 0.020 |
Why?
|
Perfusion | 1 | 2012 | 1409 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 1998 | 3041 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9602 | 0.020 |
Why?
|
T-Lymphocytes | 3 | 1994 | 10263 | 0.020 |
Why?
|
Camptothecin | 1 | 2010 | 599 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 14653 | 0.020 |
Why?
|
Models, Statistical | 2 | 2012 | 5092 | 0.020 |
Why?
|
Receptors, Fc | 1 | 1990 | 537 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2013 | 2105 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2016 | 1851 | 0.020 |
Why?
|
Epitopes | 1 | 1993 | 2526 | 0.020 |
Why?
|
Exercise | 1 | 2023 | 5945 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2012 | 1251 | 0.020 |
Why?
|
Spinal Cord Compression | 1 | 2008 | 234 | 0.020 |
Why?
|
Hepatectomy | 1 | 2010 | 589 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10384 | 0.020 |
Why?
|
Mutation | 3 | 2017 | 30214 | 0.020 |
Why?
|
Cell Line | 3 | 1997 | 15564 | 0.020 |
Why?
|
Uncertainty | 1 | 2011 | 765 | 0.020 |
Why?
|
Genetic Counseling | 1 | 2009 | 634 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4252 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 1934 | 0.020 |
Why?
|
Necrosis | 1 | 2010 | 1614 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 7057 | 0.020 |
Why?
|
Rhabdomyosarcoma | 1 | 2008 | 358 | 0.020 |
Why?
|
Triglycerides | 1 | 2013 | 2441 | 0.020 |
Why?
|
Drug Eruptions | 1 | 2008 | 335 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3600 | 0.020 |
Why?
|
Sex Distribution | 1 | 2010 | 2274 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2013 | 4853 | 0.020 |
Why?
|
Birth Weight | 1 | 2013 | 2123 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1989 | 1606 | 0.010 |
Why?
|
Morbidity | 1 | 2010 | 1754 | 0.010 |
Why?
|
Chronic Disease | 1 | 1999 | 9358 | 0.010 |
Why?
|
Age Distribution | 1 | 2010 | 2869 | 0.010 |
Why?
|
Prospective Studies | 2 | 2020 | 54872 | 0.010 |
Why?
|
Area Under Curve | 1 | 2008 | 1639 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4892 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8728 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2019 | 18329 | 0.010 |
Why?
|
Liver Transplantation | 1 | 2016 | 2416 | 0.010 |
Why?
|
Decision Making | 1 | 2017 | 3951 | 0.010 |
Why?
|
ROC Curve | 1 | 2012 | 3621 | 0.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 497 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2008 | 1615 | 0.010 |
Why?
|
Adiposity | 1 | 2013 | 1892 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9346 | 0.010 |
Why?
|
Immunotherapy | 2 | 1989 | 4747 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1989 | 1560 | 0.010 |
Why?
|
Osteosarcoma | 1 | 2008 | 908 | 0.010 |
Why?
|
Cartilage | 1 | 2006 | 811 | 0.010 |
Why?
|
Abnormalities, Multiple | 1 | 2009 | 1424 | 0.010 |
Why?
|
Diarrhea | 1 | 2008 | 1317 | 0.010 |
Why?
|
Membrane Proteins | 1 | 1998 | 7869 | 0.010 |
Why?
|
Apoptosis | 1 | 1997 | 9514 | 0.010 |
Why?
|
Nephrectomy | 1 | 2006 | 928 | 0.010 |
Why?
|
Delivery, Obstetric | 1 | 2008 | 949 | 0.010 |
Why?
|
Abscess | 1 | 2004 | 606 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2010 | 2841 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8890 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2011 | 2077 | 0.010 |
Why?
|
Forecasting | 1 | 1989 | 2936 | 0.010 |
Why?
|
Genetic Linkage | 2 | 1995 | 2342 | 0.010 |
Why?
|
Blood Vessel Prosthesis | 1 | 2004 | 956 | 0.010 |
Why?
|
Osteogenesis | 1 | 2006 | 1282 | 0.010 |
Why?
|
Prosthesis-Related Infections | 1 | 2004 | 497 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2013 | 12430 | 0.010 |
Why?
|
Kinetics | 2 | 1997 | 6288 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7430 | 0.010 |
Why?
|
Glycosylphosphatidylinositols | 1 | 1998 | 88 | 0.010 |
Why?
|
Survival Analysis | 1 | 2011 | 10101 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23618 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2010 | 2902 | 0.010 |
Why?
|
Cell Division | 2 | 1996 | 4473 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6779 | 0.010 |
Why?
|
Ultrasonography | 1 | 2011 | 5990 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12064 | 0.010 |
Why?
|
Cell Aggregation | 1 | 1997 | 238 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1997 | 238 | 0.010 |
Why?
|
Fas Ligand Protein | 1 | 1997 | 216 | 0.010 |
Why?
|
Fatty Acids | 1 | 2005 | 1806 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 1998 | 472 | 0.010 |
Why?
|
United States | 2 | 2017 | 72945 | 0.010 |
Why?
|
Age Factors | 1 | 2013 | 18397 | 0.010 |
Why?
|
Ionomycin | 1 | 1996 | 109 | 0.010 |
Why?
|
Ionophores | 1 | 1996 | 108 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13642 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 2004 | 1396 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13276 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 21527 | 0.010 |
Why?
|
Dosage Compensation, Genetic | 1 | 1995 | 209 | 0.010 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 1996 | 306 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 1996 | 521 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1997 | 1989 | 0.010 |
Why?
|
Models, Immunological | 1 | 1996 | 517 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 8045 | 0.010 |
Why?
|
Interleukin-12 | 1 | 1996 | 581 | 0.010 |
Why?
|
Chaperonin 60 | 1 | 1993 | 97 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 1996 | 4349 | 0.010 |
Why?
|
Tryptophan Oxygenase | 1 | 1992 | 19 | 0.010 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 1992 | 27 | 0.010 |
Why?
|
Interleukin-1 | 1 | 1996 | 1251 | 0.010 |
Why?
|
Interleukin-4 | 1 | 1996 | 1156 | 0.010 |
Why?
|
beta 2-Microglobulin | 1 | 1992 | 330 | 0.010 |
Why?
|
Cross Reactions | 1 | 1993 | 826 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21162 | 0.010 |
Why?
|
Granulocytes | 1 | 1992 | 551 | 0.010 |
Why?
|
Palliative Care | 1 | 2004 | 3640 | 0.010 |
Why?
|
Protein Conformation | 1 | 1995 | 3948 | 0.000 |
Why?
|
Transfection | 1 | 1995 | 5755 | 0.000 |
Why?
|
Leukocytes | 1 | 1996 | 2034 | 0.000 |
Why?
|
Diet | 1 | 2005 | 8088 | 0.000 |
Why?
|
Rabbits | 1 | 1993 | 4752 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 2005 | 22351 | 0.000 |
Why?
|
Immunotherapy, Adoptive | 1 | 1996 | 1503 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1998 | 12795 | 0.000 |
Why?
|
Interferon-gamma | 1 | 1992 | 3157 | 0.000 |
Why?
|
Monocytes | 1 | 1992 | 2599 | 0.000 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1990 | 2571 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1996 | 18986 | 0.000 |
Why?
|
Bacterial Proteins | 1 | 1993 | 3833 | 0.000 |
Why?
|
Phenotype | 1 | 1990 | 16722 | 0.000 |
Why?
|